What should you know about good news for triple-negative breast cancer?

Triple-negative breast cancer lacks receptors for oestrogen, progesterone, and HER2, so hormone-blocking medicines and HER2-directed treatment are not the usual choices. That does not mean treatment options are absent. The plan can use chemotherapy, immunotherapy for suitable tumours, surgery, radiotherapy, or a combination. Stage, lymph-node findings, overall health, inherited gene changes, and test results influence the recommendation. Encouraging news means progress in available care, not a promise about one person’s outcome.

Ask the oncology team which tests define your plan and whether the tumour has features that make immunotherapy or a PARP inhibitor relevant. Chemotherapy may be given before or after surgery. Keep a written list of medicines and symptoms, and report fever, new shortness of breath, severe diarrhoea, or other concerning effects during treatment.

Contact your treatment team promptly for fever, signs of infection, uncontrolled vomiting, dehydration, chest pain, sudden breathing difficulty, or a new severe rash. New symptoms during or after immunotherapy should be reported rather than managed alone.

Ask what makes the diagnosis triple-negative, which stage has been identified, and what each treatment is intended to do. Ask whether genetic testing is appropriate, how response will be checked, and which side effects need same-day advice.